We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Edison Pharmaceuticals Closes $20M Series F Financing

News  
Published: November 27, 2012
 
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above. ✖

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy
Read time: Less than a minute

Edison Pharmaceuticals, Inc. announced today that it has closed a Series F Preferred Financing, raising $20M. Mitsui & Co. Global Investment, Inc. led the financing and will occupy a board of directors seat.

Proceeds will be used to advance the clinical development of EPI-743. The company has recently announced the initiation of phase 2B clinical trials in the United States in two orphan mitochondrial diseases, Leigh syndrome and Friedreich's ataxia. Additional clinical development initiatives are underway and will be announced in Q1 2013.

Advertisement
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter